Copper Cu 64 Dotatate

ApprovedSmall molecule

Copper Cu 64 Dotatate is one of 45 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Neuroendocrine TumorRecruiting

Pancreatic Neuroendocrine TumorApproved

Active, not recruiting

Neuroendocrine TumorApproved

Recruiting

Competition

Competitive Landscape

60 competitors in Pancreatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

DTIC-Dome

Afinitor

8 3

Sandostatin

Glucophage

Octreotide

Sutent

5 7

FOLFOX

AstraZeneca

Phase 3

1 8

Ibrance

Pfizer

Phase 2

1 9

Sandostatin

Novartis

Phase 2

1 10

Thalomid

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedRecruiting

Neuroendocrine Tumor

NCT06016855

Clinical

Trials by Indication[1]

Neuroendocrine Tumor1 trial

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·VVanderbilt-Ingram Cancer Center·Approved·NCT06016855·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Copper Cu 64 Dotatate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Copper Cu 64 Dotatate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Copper Cu 64 Dotatate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt-Ingram Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VVanderbilt-Ingram Cancer Center

Copper Cu 64 Dotatate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News